Similar articles

• Economic analysis of Neoral in de novo renal transplant patients in Canada.

  Kingma I, Ludwin D, Dandavino R, Wolff JL, Loertscher R, Beauregard-Zollinger L, Bacquet P, Boucher S, Rivière M. Kingma I, et al. Clin Transplant. 1997 Feb;11(1):42-8. Clin Transplant. 1997. PMID: 9067694 Clinical Trial.
• Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation.

  Abella I. Abella I. Transplant Proc. 1996 Dec;28(6):3131-4. Transplant Proc. 1996. PMID: 8962213 Review. No abstract available.
• Use of cyclosporine microemulsion (Neoral) in de novo and stable renal transplantation: clinical impact, pharmacokinetic consequences and economic benefits. Canadian and International Neoral Study Groups.

  Keown PA. Keown PA. Transplant Proc. 1996 Aug;28(4):2147-50. Transplant Proc. 1996. PMID: 8769183 Clinical Trial.
• Comparison of the pharmacokinetics of cyclosporine Sandimmune with Sandimmune Neoral in stable renal transplant patients.

  Sketris IS, Lawen JG, Beauregard-Zollinger L, Belitsky P, Landsberg D, Givner ML, Keown P. Sketris IS, et al. Transplant Proc. 1994 Oct;26(5):2961-3. Transplant Proc. 1994. PMID: 7940935 Clinical Trial. No abstract available.
• Composite outcomes in renal transplantation using cyclosporine.

  Keown PA. Keown PA. Transplant Proc. 2004 Mar;36(2 Suppl):35S-39S. doi: 10.1016/j.transproceed.2004.01.060. Transplant Proc. 2004. PMID: 15041304 Review. No abstract available.